A child sitting on the boardwalk with a red skateboard - Sobi

WE CARE ABOUT RARE DISEASE PATIENTS

Sobi is dedicated to developing and delivering innovative therapies to improve the lives of rare disease patients.
Two girls holding hand

North America News

FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)

Sobi tank in factory

Our Products

Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.

Smiling woman

Global News

FDA approves Gamifant® (emapalumab), the first and only treatment for primary haemophagocytic lymphohistiocytosis (HLH)

Sobi map

Sobi United States Office

890 Winter Street

Waltham, MA 02451, USA


Sobi Canada Office

1155 North Service Rd. West, Unit #11

Oakville, Ontario, Canada L6M 3E3

All contacts